Document is current

Article History

Accepted: 24 October 2024

First Online: 26 November 2024

Declarations

:

: Open Access funding enabled and organized by Projekt DEAL. The authors are financially supported by the German Research Foundation (Deutsche Forschungsgemeinschaft), grant 338/1 2021-452881907, project A02 (MH) [LETSimmun], the German Research Foundation (Deutsche Forschungsgemeinschaft), grant SFB/ TRR221, project A03 (MH) [GvH/GvL], the Fraunhofer Internal Progams under Grant No. Attract 40-07171 (MH), the Bavarian Center for Cancer Research (Bayerisches Zentrum fur Krebsforschung, Leuchtturm Immuntherapien (MH), the German Cancer Aid (Stiftung Deutsche Krebshilfe), grant 70114707 (TransOnc Avant-CAR.de (Michael Hudecek) and grant 70115200 (CAR FACTORY [MH], the Federal Ministery for Education and Research (Bundesministrium für Bildung und For-schung), grant 13N15987 (IMAGINE [MH], grant 01EN2306A (ROR2 CAR-T [MH], and grant 03ZU1111BA (SaxoCell), Innovative Medicine Initiative 2 Joint Undertaking (JU), grant 853988 (imSAVAR) and grant 945393(T2EVOLVE). The JU receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA and JDRF International. Addtional funding was provided by the patient advocacy group Hilfe im Kampf gegen den Krebs e.V. (MH), and by the non-profit organization Forschung hilft - Stiftung zur Förderung der Krebsforschung an der Universität Würzburg“ (MH) and Gilead cell therapy grant (grant ID20963) [AGT].

: Katrin Mestermann is listed as a co-inventor on a patent application related to the use of dasatinib in the context of CAR-T immunotherapy that has been filed by the University of Würzburg (PCT/EP2018/084018, “Control and modulation of the function of gene-modified chimeric antigen receptor T cells”). Andoni Garitano-Trojaola has no conflicts of interest that are directly relevant to the content of this article. Michael Hudecek is listed as a co-inventor on patent applications and granted patents related to CAR technologies and CAR-T therapy that have been filed by the Fred Hutchinson Cancer Research Center, Seattle, WA, USA and the University of Wuerzburg, Wuerzburg, Germany that have been, in part, licensed to industry. Michael Hudecek is a co-founder and equity owner of T-CURX GmbH, Wuerzburg, Germany. Michael Hudecek further declares speaker’s honoraria from Novartis, Kite/Gilead, BMS/Celgene, and Janssen.

: Not applicable.

: Not applicable.

: Not applicable.

: No datasets were generated or analyzed during the current study.

: Not applicable.

: KM and AGT wrote the manuscript. MH revised the manuscript.